Guardant Health Launches Shield Colorectal Cancer Test in South Korea

Guardant Health has launched its blood-based colorectal cancer (CRC) screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea, where CRC is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths.

Shield test is an innovative test that can detect cancer in its early stages by analysing circulating tumour DNA (ctDNA), which is produced when tumours shed small pieces of their genetic material into the bloodstream. In the pivotal ECLIPSE study of more than 20,000 patients, the Shield test achieved 83% sensitivity and 90% specificity for detecting colorectal cancer in average-risk adults in the US.

The Shield blood test can broaden the range of choices for colorectal cancer screening. We are confident that by introducing a high-quality blood-based screening test, we can meet the needs of both patients and healthcare providers and help improve screening compliance,” said Health Promotion Center of Samsung Medical Center.

We are pleased to launch the Shield test at Samsung Medical Center and are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it’s most treatable, with a simple blood draw,” said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.

en_GBEnglish (UK)